Ascendis Pharma AS ADR ASND
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
New 3-Year Skeletal Dynamics Data for Adults with Hypoparathyroidism Treated with TransCon™ PTH (Palopegteriparatide) Presented at ASBMR 2024
-
Ascendis Pharma Announces Submission of Supplemental Biologics License Application to FDA for TransCon™ hGH for the Treatment of Adults with Growth Hormone Deficiency
-
Ascendis Pharma A/S Announces Pricing of Public Offering of ADSs
-
Ascendis Pharma A/S Announces Proposed Public Offering of ADSs
-
Pivotal ApproaCH Trial of TransCon™ CNP (Navepegritide) Achieved Primary Objective, Demonstrated AGV Superior to Placebo
-
Ascendis to Present First Results from Platinum-Resistant Ovarian Cancer (PROC) Cohort of the Phase 1/2 IL-Believe Trial at ESMO 2024
-
Ascendis Pharma Gets Orphan Drug Exclusivity for Hormone Treatment Yorvipath in U.S.
-
Ascendis Pharma Receives Orphan Drug Exclusivity in the U.S. for YORVIPATH® (Palopegteriparatide) for the Treatment of Hypoparathyroidism in Adults
Trading Information
- Previous Close Price
- —
- Day Range
- —–—
- 52-Week Range
- —–—
- Bid/Ask
- — / —
- Market Cap
- —
- Volume/Avg
- — / —
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 24.17
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Ascendis Pharma AS is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates in North America, China, and Europe and derives the majority of its revenue from North America.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- —
- Total Number of Employees
- 879
- Website
- https://www.ascendispharma.com
Valuation
|
Metric
|
ASND
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | 24.17 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
ASND
|
|---|---|
Quick Ratio | 0.40 |
Current Ratio | 0.74 |
Interest Coverage | −3.80 |
Quick Ratio
ASND
Profitability
|
Metric
|
ASND
|
|---|---|
Return on Assets (Normalized) | −52.65% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | −66.73% |
Return on Assets
ASND
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Tmjnfxvpp | Jbcdh | $518.0 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Stwqhwxxv | Yhwsqk | $119.3 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Pxycfmsnl | Tldkmty | $114.7 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Vmhtxhhd | Wkfkkhd | $34.9 Bil | |||
| argenx SE ADR
ARGX
| Htfvrxrv | Gnkg | $32.9 Bil | |||
| BioNTech SE ADR
BNTX
| Zbyncfd | Nyzq | $28.3 Bil | |||
| Moderna Inc
MRNA
| Xvzynttp | Hby | $24.3 Bil | |||
| United Therapeutics Corp
UTHR
| Dwmhlbjdx | Yrcc | $15.7 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Gcmslkqx | Gdvdxmv | $13.3 Bil | |||
| Incyte Corp
INCY
| Sdyrbfry | Lswxrzk | $13.0 Bil |
United States